Most dengue infections occur in pre-adolescents and young adults. e age group of 15-44 years has been found to be consistently at the highest risk for dengue in Singapore; about 62.5 percent cases belonged to this age group from 2002 to 2014. 8, 9 Severity of the Disease e clinical spectrum of dengue is highly unpredictable. e disease is classi ed by WHO into two distinct categories: dengue that occurs with or without warning signs. Both of these can develop into severe dengue, characterised by plasma leakage, uid accumulation with respiratory distress, severe bleeding, organ impairment, and subsequent hospitalisation and death. 2, 10, 11 ere are multiple factors a ecting dengue severity, including virulence of the infecting serotype, host genetics, and age. 12 Although antibody-dependent enhancement (ADE) has been demonstrated in vitro, and hypothesised to cause severe dengue, pre-existing in vitro ADE levels have not been shown to correlate with disease severity upon natural infection.
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DENGVAXIA®: THE FIRST DENGUE VACCINE LICENSED IN THE WORLD
Overview
Dengvaxia® is the rst dengue vaccine to be licensed in the world; currently, Dengvaxia® is approved in 18 countries. 14 Over 20 years of research have been invested into the development of this recombinant, live-attenuated vaccine. 15 Dengvaxia® is a technological advancement, developed by removing the genes coding for structural proteins (while 
OVERVIEW OF DENGUE Background and Epidemiology
Dengue is the most rapidly spreading mosquito-borne viral disease in the world. retaining the genes coding for capsid and non-structural proteins) from the yellow fever vaccine virus (YF 17D204) backbone and replacing with genes coding for dengue structural proteins for all 4 serotypes. [16] [17] [18] Clinical Efficacy and Safety of Dengvaxia® e clinical development programme of Dengvaxia® has been robust, with about 25 clinical studies (5 phase I, 14 phase II and 6 phase III studies) conducted in more than 40,000 subjects across 15 countries. 19, 20 Early phase I/II clinical trials, including the phase II CYD28 trial conducted in Singapore, showed a balanced immune response of the vaccine against the 4 DENV serotypes after 3 doses and a safety/reactogenicity pro le comparable to the control vaccines. 15, 21, 22 In the CYD28 trial (n=1198), it was also noted that a vaccination schedule of 3 doses must be completed for attaining adequate geometric mean neutralising antibody titres (GMTs); the attained mean GMT titres were stable for up to 4 years of follow-up. 22 Large-scale e cacy and safety studies of Dengvaxia® have been conducted in 10 countries in more than 30,000 participants. 19, 20 e phase III Asian study (CYD14) was conducted in more than 10,000 children (aged 2-14 years) in ve highest dengue-endemic countries in Asia, namely Vietnam, ailand, Malaysia, Indonesia and the Philippines. is study involved two phases: a 25-month active surveillance phase for assessing the e cacy of the vaccine and a 4-year long-term follow-up (LTFU) phase for assessing the long-term safety of the vaccine.
e study concluded that Dengvaxia® has a good safety pro le, is e ective in protecting against all 4 DENV strains and reduces the incidence of severe disease and hospital admissions. Furthermore, it was noted that the e cacy of the vaccine was higher in individuals with pre-existing dengue neutralising antibodies than in seronegative individuals, and in older age cohorts as compared to a younger population 23 . e phase III CYD15 study was conducted in the highest dengue-endemic countries of Latin America and the Caribbean. is study had similar design and objectives as the CYD14 study and enrolled more than 20,000 subjects aged 9-16 years. e study reported that the vaccine was e cacious against virologically con rmed dengue (VCD) and severe VCD, and was associated with a clinically signi cant reduction in hospitalisations for VCD. Furthermore, similar to the CYD14 study, this study also reported a higher e cacy of the vaccine in seropositive versus seronegative individuals. 24 A meta-analysis of the results of the active surveillance phases of CYD14 and CYD15 in 13,732 subjects aged 12-16 years revealed that the vaccine was e cacious against all DENV serotypes ( Figure 2) . 25 is analysis formed the basis for the approval of the vaccine in Singapore in the age group of 12-45 years. e approval of the upper age limit of 45 years, despite the availability of e cacy data only up to the age of 16 years, is based on the concept of immunological bridging. According to this theory, the mechanism of action of Dengvaxia® is based on the production of neutralising antibodies, 26 and the GMTs of antibodies after the third injection have been noted to be higher in phase II immunological studies in individuals aged years, compared to the titres noted in CYD14 and CYD15 studies, which enrolled individuals aged up to 16 years. 23, 24, 27, 28 erefore, it is anticipated that adults up to 45 years of age living in endemic areas will produce similar levels of antibodies and have similar levels of protection compared with the adolescent population. is concept of immunological bridging is a method cited by the WHO and used by various other vaccines.
OPTIMISING THE USE OF DENGVAXIA® BASED ON SEROLOGICAL STATUS
According to the 2016 statistics, more than 50 percent of individuals aged >40 years have been found to be seropositive in Singapore (Table 1) 29 .
A supplementary analysis (NS1 study) of the e cacy data of the phase IIb/III studies was conducted recently to further assess the e cacy of the vaccine in individuals with or without prior dengue infection. A new assay was developed by the University of Pittsburgh and used by Sano for this analysis, which enabled the detection of antibodies against the dengue non-structural protein 1 (NS1). is distinguished the immune responses due to past dengue infection from those due to vaccination, thus enabling the categorisation into seropositive or seronegative at the time of receiving the rst dose of the vaccine. e results showed a clear bene t in vaccinating seropositive individuals, and an unfavourable bene t-risk pro le in seronegative individuals who were vaccinated ( Figure  3 ). Despite this, the cases of severe dengue noted in seronegative vaccine recipients were primarily dengue haemorrhagic fever (DHF) grades I and II, and did not lead to shock, severe bleeding or death; recovery was noted in all patients 30 . e ndings from this new analysis for optimising the use of Dengvaxia® based on the serological status is shown in Table 2 .
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Based on the ndings from this new analysis, a revision in the warning and adverse event section of the Dengvaxia® label has been proposed. According to this update, (1) Dengvaxia® should only be recommended when the potential bene ts outweigh the potential risks (in countries with a high burden of dengue disease); and (2) vaccination should not be recommended in individuals who have not been previously infected by DENV. Table 2 : Five-year risk of severe dengue in vaccinated/ unvaccinated individuals based on serostatus
